MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12885-026-15801-0

Медицинская библиотека · BMC cancer · 2026

Association between cholesterol and liver injury risk in solid cancer patients treated with PD-1 inhibitors: evidence from two cohort studies.

Lei Jing, Wang Yi, Jin Zhiping, Qin Guoyou, Liu Tianshu, Zhang Ningping, Lv Minzhi

СтатьяПеревод в очереди

Аннотация

BACKGROUND

To assess the association between baseline serum lipids and the risk of severe hepatic immune-related adverse events (irAEs) in solid cancer patients treated with PD-1 inhibitors.

METHODS

This retrospective study included a discovery cohort (N = 601) and an independent high-risk population validation cohort (N = 331), all of whom received PD-1 inhibitor therapy at Zhongshan Hospital between 2019 and 2023. Baseline levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG) were measured prior to treatment. Hepatic irAEs were systematically evaluated using the CTCAE and RUCAM scores, with grade ≥ 3 (G3+) defined as severe. Restricted cubic spline models and multivariable Cox regression analyses were used to evaluate the associations between baseline lipid levels and the risk of hepatic irAEs.

RESULTS

In the discovery cohort, nonlinear associations were observed between baseline TC and LDL-C levels and the risk of G3+ hepatic irAEs (P-value TC=0.021, P-value LDL−C=0.034). Compared with the reference group (LDL-C: 2.47–3.37 mmol/L), patients with elevated LDL-C levels (≥ 3.37 mmol/L) had a significantly increased risk of severe hepatic irAEs (HR = 2.16, 95% CI: 1.13–4.10, P-value = 0.019). Similar associations of elevated LDL-C levels (≥ 3.37 mmol/L) were validated in the high-risk population (HR = 2.09, 95% CI: 1.01–7.73). No significant associations were found between HDL-C or TG levels and the risk of hepatic irAEs. Sensitivity analyses demonstrated consistent results, which were confirmed in the validation cohort.

CONCLUSIONS

Elevated baseline LDL-C levels were associated with an increased risk of severe hepatic irAEs in solid cancer patients receiving PD-1 inhibitor therapy. This finding highlights the importance of pre-treatment lipid risk stratification and monitoring in immunotherapy patients.

Для цитирования: Lei Jing, Wang Yi, Jin Zhiping, Qin Guoyou, Liu Tianshu, Zhang Ningping, Lv Minzhi. Association between cholesterol and liver injury risk in solid cancer patients treated with PD-1 inhibitors: evidence from two cohort studies.. BMC cancer. 2026. DOI: 10.1186/s12885-026-15801-0.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.